6 days Ago By ABMN Staff
XTX Topco Ltd bought a new stake in Kura Oncology, Inc. ( NASDAQ:KURA – Free Report ) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,669 shares of the company’s stock, valued at approximately $180,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Barclays PLC lifted its position in Kura Oncology by 104.5% during the third quarter.
Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after purchasing an additional 84,563 shares during the last quarter. Franklin Resources Inc. lifted its position in Kura Oncology by 1.
5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock valued at $28,687,000 after purchasing an additional 23,113 shares during the last quarter.
JPMorgan Chase & Co. lifted its position in Kura Oncology by 0.8% during the third quarter.
JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the last quarter. Harbor Capital Advisors Inc.
lifted its position in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc.
now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Kura Oncology during the fourth quarter valued at approximately $436,000. Kura Oncology Trading Up 1.
2 % NASDAQ:KURA opened at $6.51 on Tuesday. The company has a quick ratio of 11.
47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.
The company has a fifty day moving average of $6.85 and a 200 day moving average of $9.85.
The firm has a market capitalization of $525.86 million, a P/E ratio of -2.76 and a beta of 0.
83. Kura Oncology, Inc. has a 52 week low of $5.
41 and a 52 week high of $23.48. Wall Street Analysts Forecast Growth A number of equities research analysts have recently weighed in on the stock.
BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Scotiabank lowered their price objective on shares of Kura Oncology from $18.00 to $10.
00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. UBS Group lowered their price objective on shares of Kura Oncology from $27.00 to $14.
00 and set a “buy” rating for the company in a report on Thursday, March 6th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Monday.
Finally, StockNews.com upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Friday, April 4th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock.
According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.50.
View Our Latest Research Report on Kura Oncology About Kura Oncology ( Free Report ) Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Further Reading Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. ( NASDAQ:KURA – Free Report ).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter ..
